43 completed, 25 recruiting, 7 active not recruiting, 7 unknown. 93 Phase 3, 7 Phase 2.
Follow Topotecan: new trials by email Literature Review of Topotecan trials Research Report on Topotecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer JSKN033, Docetaxel, Topotecan - Recurrent or Metastatic Cervical Cancer | Phase 3 | Not yet recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 368 | 2026-09-01 | 2026-09-01 |
| A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers SYS6043, Liposomal doxorubicin, paclitaxel, or topotecan - Platinum-resistant Ovarian Cancer, Platinum-resistant Primary Peritoneal Cancer | Phase 3 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 460 | 2026-07-15 | 2026-09-23 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer ABBV-706, Topotecan, Lurbinectedin - Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 531 | 2026-07-02 | 2026-09-23 |
| A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer BL-M07D1, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-07-01 | 2026-06-29 |
| An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer | Phase 3 | Recruiting | Genmab | 82 | 2026-06-26 | 2026-11-03 |
| A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD) - Ovarian Neoplasms | Phase 3 | Recruiting | GlaxoSmithKline | 450 | 2026-06-18 | 2026-10-15 |
| A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer SHR-A2102 for Injection, Pemetrexed Disodium for Injection, Gemcitabine Hydrochloride for Injection - Recurrent Cervical Cancer, Metastatic Cervical Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 398 | 2026-03-30 | 2026-04-06 |
| AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel - Epithelial Ovarian Cancer | Phase 3 | Recruiting | AstraZeneca | 1100 | 2025-12-29 | 2026-07-21 |
| Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer ZG006, Topotecan - Small-cell Lung Cancer | Phase 3 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 420 | 2025-12-12 | 2026-01-05 |
| Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression INCB123667, Investigator's choice of chemotherapy - Ovarian Cancer | Phase 3 | Recruiting | Incyte Corporation | 466 | 2025-12-09 | 2026-10-15 |
| A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer Sofetabart Mipitecan, Paclitaxel, Topotecan - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 3 | Recruiting | Eli Lilly and Company | 1630 | 2025-10-22 | 2026-11-04 |
| A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] Risvutatug rezetecan (Ris-Rez), Topotecan - Neoplasms, Lung | Phase 3 | Recruiting | GlaxoSmithKline | 420 | 2025-08-11 | 2026-10-20 |
| A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 450 | 2025-08-04 | 2026-07-07 |
| Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer Organoid Drug Sensitivity Testing-Guided Therapy, Topotecan - Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive-stage Small Cell Lung Cancer (SCLC) | Phase 2 / Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 128 | 2025-08-01 | 2025-08-06 |
| A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer MHB088C for Injection, Topotecan, Irinotecan - Small Cell Lung Cancer Extensive Stage | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 450 | 2025-06-04 | 2025-06-18 |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only) - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 3 | Recruiting | Gilead Sciences | 695 | 2025-04-04 | 2026-10-20 |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma Biospecimen Collection, Bone Scan, Computed Tomography - Pleuropulmonary Blastoma | Phase 3 | Recruiting | Children's Oncology Group | 110 | 2025-03-21 | 2026-08-25 |
| HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer HS-20089, Paclitaxel, Doxorubicin - Ovarian Cancer | Phase 3 | Recruiting | Hansoh BioMedical R&D Company | 468 | 2025-03-13 | 2025-12-17 |
| A Study of SHR-A1811 in Subjects With Ovarian Cancer SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection - Ovarian Cancer | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 300 | 2025-03-13 | 2026-04-20 |
| Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer | Phase 3 | Active not recruiting | Genmab | 584 | 2025-02-07 | 2026-11-03 |
Showing 20 of 93. Sign in to see all of them.
Ovarian Neoplasms (31) · Small Cell Lung Carcinoma (26) · Fallopian Tube Neoplasms (15) · Carcinoma, Ovarian Epithelial (9) · Uterine Cervical Neoplasms (9) · Neuroblastoma (7) · Lung Neoplasms (6) · Neoplasms (3) · Retinoblastoma (3) · Sarcoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Ganglioneuroblastoma (2) · Malignant mesenchymal tumor (2) · Neoplasm Metastasis (2) · Recurrence (2)
Children's Oncology Group (8) · GlaxoSmithKline (6) · National Cancer Institute (NCI) (4) · AbbVie (3) · Gynecologic Oncology Group (3) · PharmaMar (3) · Sichuan Baili Pharmaceutical Co., Ltd. (3) · AGO Study Group (2) · Case Comprehensive Cancer Center (2) · Daiichi Sankyo (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · Genmab (2) · Hansoh BioMedical R&D Company (2) · Hoffmann-La Roche (2) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd (2)
United States (48) · China (37) · Canada (33) · Germany (32) · Spain (31) · Italy (30) · France (28) · Belgium (27) · Australia (26) · United Kingdom (26) · Poland (22) · South Korea (22) · Hungary (19) · Netherlands (19) · Brazil (17)
Jalid Sehouli (2) · Nathan Levitan, MD (2) · Bradley Monk (1) · Caicun Zhou (1) · Carola Arndt (1) · Ciro Gallo, M.D., Ph.D. (1)
PMID 37407274, PMID 16882940, PMID 37185961, PMID 10655437, PMID 10882162, PMID 11165136, PMID 11304695, PMID 11479630, PMID 12165894, PMID 12880954, PMID 15911864, PMID 15911865, PMID 16129365, PMID 16216315, PMID 16912194, PMID 17513814, PMID 19427025, PMID 21328522, PMID 21376569, PMID 21835933, PMID 23397080, PMID 23410977, PMID 23890779, PMID 23969788, PMID 24419114, PMID 24552320, PMID 24637997, PMID 24687829, PMID 24779680, PMID 25638326, PMID 27465021, PMID 27871723, PMID 28481967, PMID 28595285, PMID 28756902, PMID 29290251, PMID 29462248, PMID 30444686, PMID 30633128, PMID 31386611, PMID 31420414, PMID 31454045, PMID 32530765, PMID 32847980, PMID 32888454, PMID 33507604, PMID 33667670, PMID 34028986, PMID 34521554, PMID 34607820
2025 (5), U10CA180886 (5), 2023 (3), U10CA027469 (3), U10CA098543 (3), U10CA180868 (3), 2008 (1), 2009 (1), 2015 (1), 2016 (1), 2017 (1), 2019 (1), P01CA023099 (1), P30CA013330 (1), P50CA083639 (1)